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Abstract 
Multidrug resistance (MDR) is a critical problem in the chemotherapy of cancers. Human 
hepatocellular carcinoma (HCC) responds p o o r l y   t o   c h e m o t h e r a p y   o w i n g   t o   i t s   p o t e n t   M D R .  
Chemotherapeutic drugs primarily act by inducing apoptosis of cancer cells, and defects in 
apoptosis may result in MDR. Mitochondrial permeability transition (mPT) is implicated as an 
important event in the co n t r o l   o f   c e l l   d e a t h   o r   s u r v i v a l   a n d   m P T   r e p r e s e n t s   a   t a r g e t   f o r   t h e  
development  of  cytotoxic  drugs.  This  study  aimed  to  investigate  the  effects  of  selective 
opener (Atractyloside glycoside, ATR) and inhibitor (Cyclosporine A, CsA) of mitochondrial 
permeability transition pore (mPTP) on a CDDP-resistant HCC cell line (SK-Hep1 cells). In 
this study, a stable MDR phenotype characterization of SK-Hep1 cell line (SK-Hep1/CDDP 
c e l l s )   w a s   e s t a b l i s h e d   a n d   u s e d   t o   i n v e s t i g a t e   t h e   r o l e   o f   m P T P   i n   M D R .   R e s u l t s   s u g g e s ted that 
ATR accelerated the decrease of mitochondrial membrane potential (ΔΨm ) ,   r e d u c e d   t h e   B a x  
activity, and increased the apoptosis of SK-Hep1/CDDP cells; while CsA inhibited mPTP 
opening, reduced and delayed the decline of mitochondrial membrane potential,  and  in-
creased the Bax activity, leading to increased tolerance of SK-Hep1/CDDP cells to apoptosis 
induction.  However,  mPTP  activity  had  no  effect  on  the  expression  of  MDR1  in 
cells,meanwhile the P-gp translocation to mitochondria was increased, and functionally acti-
vated. I n   c o n c l u s i o n ,   s e l e c t i v e   m o d u l a t i o n   o f   m P T P   c a n   a f f e c t   M D R   i n   h u m a n   H C C   c e l l s .  
T h e r e f o r e ,   a c t i v a t i o n   o f   m P T P   m a y   p r o v i d e   a   n e w   s t r a t e g y   t o   s e n s i t i z e   c a n c e r   c e l l s   t o   c h e-
motherapeutic drugs and to reverse the MDR in cancer cells. 
Key words: hepatocellular carcinoma, mitochondrial permeability transition pore, multidrug re-
sistance, mitochondrial membrane potential. 
Introduction 
Hepatocellular  carcinoma  (HCC)  is  the  most 
c o m m o n   t u m o r   w o r l d w i d e ,   a n d   t h e   t h i r d   m o s t   c o m-
m o n   c a u s e   o f   c a n c e r   d e a t h ,   o f t e n   a c c o m p a n i e d   w i t h  
poor prognosis  [1-3]. A majority of patients are sur-
gically  un-resectable  at  the  time  of  diagnosis,  and 
even for those surgery is possible, the risk of recur-
rence is extremely high. Consequently, chemotherapy 
is an important strategy for most HCC patients. Cis-
platin has been used as a common chemotherapeutic 
a g e n t   f o r   H C C .   H o w e v e r ,   t h e   H C C   s t i l l   p o o r l y   r e-
s p o n d s   t o   C i s p l a t i n   d u e   t o   i t s   i n t r i n s i c   o r   a c q u i r e d  
m i t l d r u g   r e s i s t a n c e   ( M D R )   a n d   t h e   s u r v i v a l   o f   H C C  
patients  is  unfavorable  [4,5].  Multidrug  resistance 
(MDR)  is a   c r i t i c a l   p r o b l e m   i n   t h e   c h e m o t h e r a p y   o f  
cancers  [6].  MDR  describes  a  phenomenon  of 
cross-r e s i s t a n c e   o f   t u m o r   c e l l s   t o   s e v e r a l   s t r u c t u r a l l y  
and functionally unrelated antitumor drugs after ex-
posure to a single cytotoxic drug. But the exact me-
chanism of MDR remains unclear.  
Mitochondria  not  only  provide  the  essential 
e n e r g y   f o r   l i f e   a c t i v i t i e s ,   b u t   a l s o   t a k e   p a r t   i n   v a r i o u s  
s i g n a l   t r a n s d u c t i o n s .   I n d u c t i o n   o f   a p o p t o s i s   i s   a  
common way in which chemotherapy drugs eliminate 
tumor cells. Nowadays, mitochondria now represent Int. J. Biol. Sci. 2010, 6 
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a novel target in cancer chemotherapy [7]. Regulation 
of  mitochondrial  function  can  not  only  protect  the 
normal cells from the initiation of apoptosis, but also 
induce  the  release  of  apoptotic  proteins  leading  to 
apoptosis of tumor cells.  
Mitochondrial permeability transition (mPT) is 
implicated in apoptosis or necrosis as an important 
e v e n t   i n   t h e   c o n t r o l   o f   c e l l   d e a t h   o r   s u r v i v a l .   O p e n i n g  
of mitochondrial permeability transition pore (mPTP) 
renders the cancer cells to show the characteristics  of 
apoptosis by promoting the release of apoptotic pro-
t e i n .   T h u s ,   m o d u l a t i o n   o f   m P T P   m a y   p r o v i d e   a   n e w  
strategy for the reversal of MDR. 
In the present study, a MDR hepatocellular car-
cinoma cell line (SK-Hep1/CDDP) was established to 
investigate the ro l e   o f   m P T P   i n   t h e   M D R   o f   c a n c e r  
c e l l s .   O u r   s t u d y   m a y   p r o v i d e   a   n e w   s t r a t e g y   f o r   t h e  
reversal of MDR in cancer cells.  
Materials and methods 
Reagents 
Cisplatin (CDDP),  doxorubicin  (DOX),  penicil-
lin,  streptomycin,  propidium  iodide (PI),  RNase A, 
Rho123  and  Atractyloside  glycoside  (ATR)  were 
purchased from the Sigma-Aldrich Chemical Co (St. 
Louis,  MO,  USA).  Vincristine  (VCR)  was  from 
Shenzhen Main Luck Pharmaceuticals Inc. (Shenzhen, 
China),5-fluorouracil  (5-FU)from  Shanghai  Xudong 
Haipu  Pharmaceutical  Co.  Ltd  (Shanghai,  China), 
Cyclosporine  A(  CsA)  from  Novartis  (Sandimmun, 
Novartis Pharma AG, Stein, Switzerland), Dulbecco’s 
modified Eagle’s medium (DMEM), fetal bovine se-
rum  (FBS)  and  Trypsin  from  Invitrogen  (Carlsbad, 
CA,  USA).  The  phospho-glycoprotein  (P-gp)  MDR1 
mouse  monoclonal  antibody  and  FITC-conjugated 
goat anti-mouse IgG were purchased from Santa Cruz 
B i o t e c h n o l o g y   ( S a n t a   C r u z ,   C A ,   U S A ) ,   M i t o T r a c k e r  
R e d   C M X R o s   d y e   f r o m   I n v i t r o g e n   ( M o l e c u l a r   P r o b e s ,  
Invitrogen  Corp.),  JC-1  from  Cell  Technology  Inc., 
USA, Cell Counting Kit-8 (CCK-8) from Dojindo Mo-
lecular  Technologies  (Dojindo,  Japan),  Annexin 
V-FITC/PI  apoptosis  detection  kit  from  Nanjing 
KeyGen  Biotech  Co.,  Ltd  (Nanjing, China),  and  cell 
culture supplies from Corning Life Sciences (Lowell, 
MA,  USA).  Anti-tumor  agents  were  prepared  with 
complete culture medium immediately prior to use.  
Cell line and culture 
The  human  HCC  cell line SK-Hep1  cells (pur-
chased from Cell Culture Center, Institute of Bioche-
mistry  and  Cell  Biology,  Chinese  Academy  of  Life 
Sciences, Shanghai) were maintained in high glucose 
DMEM (DMEM/H) containing 10% (v/v) fetal bovine 
serum (FBS), penicillin (200 U/mL), and streptomycin 
(100 μg/mL) at 37°C in a humidified air with 50 mL/L 
CO2. Approximately 1.0x105  cells  were  seeded  in  a 
25-m m   d i s h ,   a n d   t h e   m e d i u m   w a s   r e f r e s h e d   2 4   h   l a t e r .  
Two  to  three  days  later,  these  cells  were 
sub-cultivated  following  digestion  with  0.25  g/L 
trypsin, and seeded in another 25-mm dish. 
Establishment of SK-Hep1 cells resistant to 
CDDP (SK-Hep1/CDDP)  
CDDP-resistant  SK-Hep1  (SK-Hep1/CDDP) 
cells were established by pulse exposure of SK-Hep1 
c e l l s   t o   h i g h   c o n c e n t r a t i o n   ( 5   μ g / m l )   o f   C D D P   f o r  
short  periods  over  24  h  as  previously  reported  [8]. 
Briefly, SK-H e p 1   c e l l s   w e r e   w a s h e d   w i t h   0 . 0 1   m o l / L  
PBS and grown in CDDP-free growth medium for one 
t o   t w o   d a y s .   F o l l o w i n g   w a s h i n g   w i t h   P B S ,   t h e s e   c e l l s  
were  maintained  in  a  fresh  medium.  The  resistant 
cells  were  isolated  by  limiting  dilution  of 
cis-Diaminedichloroplatinum(CDDP). After 4 weeks’ 
incubation  at  37 °C in a humidified air with 50 mL/L 
CO2, the cells recovered at an exponential rate and 
were  then  sub-cultivated.  Once  cell  confluence 
reached 60–70%, the procedures above were repeated. 
The  acquired  resistance  was  confirmed  when  these 
cells were able to maintain logarithmic growth upon 
addition  of  cisplatin  to  the  medium.  The 
CDDP-resistant cells were established 6 months later. 
For  maintenance  of  CDDP-resistant  cells,  the 
SK-Hep-1 / C D D P   c e l l s   w e r e   g r o w n   i n   t h e   p r e s e n c e   o f  
0 . 0 1   μ g / m L   C D D P .   B e f o r e   e x p e r i m e n t ,  
SK-Hep-1 / C D D P   c e l l s   w e r e   m a i n t a i n e d   i n   a  
CDDP-free medium and passaged at least 3 times.  
Cell preparation 
SK-H e p 1   a n d   S K -H e p 1 / C D D P   c e l l s   w e r e   m a i n-
tained  at  37°C  in  humidified  air  with  5%CO2  in 
DMEM/H containing 10% FBS, 200 U/mL penicillin, 
and 100 μg/mL streptomycin. Cells were divided into 
the following groups: ①SK-Hep1  cells;  ②1 µM  CsA 
treated SK-Hep1 cells; ③20 µM ATR treated SK-Hep1 
cells;  ④SK-Hep1/CDDP  cells;  ⑤ 1 µM  CsA  treated 
SK-Hep1/CDDP  cells;  ⑥ 20  µM  ATR  treated 
SK-Hep1/CDDP cells. All cells were grown for 24 h. 
Cytotoxicity of CDDP determined by CCK-8 
assay 
The  cytotoxicity  of  CDDP  was  determined  in 
d i f f e r e n t   g r o u p s   b y   C C K -8 assay according to manu-
facturer’s instructions.The absorbance (A) represents 
t h e   n u m b e r   o f   v i a b l e   c e l l s   a n d   i s   d e t e c t e d   w i t h   e n-
zyme-linked  immunosorbent  assay  (ELISA;  measur-
ing  wavelength:  450  nm;  reference  wavelength:  650 
nm) in a microplate reader. Relative inhibition rate 
was calculated as follow: relative inhibition rate (%) = 
(1-A   o f   t r e a t e d   w e l l / A   o f   c o n t r o l   w e l l ) × 1 0 0 % ,   a n d   t h e Int. J. Biol. Sci. 2010, 6 
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half  maximal  inhibitory  concentration  (IC50)  was 
c a l c u l a t e d   w i t h   t h e   S P S S   v e r s i o n   1 3 . 0   s t a t i s t i c   s o f t w a r e  
package. The resistance index (RI) was calculated as 
f o l l o w :   R I   =   I C 5 0   o f   r e s i s t a n t   c e l l s / I C 5 0   o f   p a r e n t a l  
cells. 
Flow cytometric analysis using Annexin V/PI 
double-staining 
The changes in cell apoptosis were detected with 
FITC-annexin V/PI double-fluorescence labeling and 
subsequent  flow  cytometry  (FCM).  Cells  of  each 
group were seeded into 6-well plate in triplicate at a 
density of 1×105 cells/mL. Following treatment with 
10 µg/mL CDDP for 24 h, cells were harvested and 
cell  density  was  adjusted  to  1×105/mL  followed  by 
centrifugation at 1500 rpm for 5 min. The supernatant 
w a s   r e m o v e d ,   a n d   t h e   c e l l s   w e r e   i n c u b a t e d   i n   5   μ L   o f  
Annexin V, 195 μL of buffer and 20 μL of PI for 20 min 
in  dark.  Then,  5×104 c e l l s   w e r e   c o l l e c t e d   f r o m   e a c h  
g r o u p   f o l l o w e d   b y   f l o w   c y t o m e t r y   a t   t h e   e x c i t a t i o n  
wavelength  of  488  nm.  Data  were  analyzed  using 
Cellquest software with untreated SK-Hep1 cells and 
SK-Hep1/CDDP cells as controls.  
Evaluation of mitochondrial membrane potential 
(ΔΨm) by JC-1 staining assay 
Mitochondrial  membrane  potential  (ΔΨm)  was 
detected with JC-1 mitochondrial membrane potential 
detection  kit  following  the  manufacturer’s  instruc-
tions.  Briefly,  5×106  cells  were  collected  and 
re-s u s p e n d e d   i n   1   m L   o f   m e d i u m .   A f t e r   a d d i n g   1   m L  
of working solution of JC-1   d y e ,   t h e   c e l l s   w e r e   m i x e d  
thoroughly and incubated at 37 ℃ for 20 min in dark. 
The excessive dye was removed by washing with JC-1 
staining buffer. Cells were centrifuged at 1000 rpm for 
3 min at room temperature, and the supernatant was 
r e m o v e d .   T h e   c e l l s   w e r e   t h e n   r e -suspended in 500 μL 
of JC-1 staining working solution by slightly shaking 
and monitored under laser scanning confocal micro-
scope (Leica   T c s   S P 2 ,   G e r m a n y ) .   J C -1 monomer (green 
fluorescence)  has  excitation  wavelength  of  488  nm 
and emission wavelength of 505~530 nm. When the 
ΔΨm is low, JC-1   e x i s t s   m a i n l y   i n   t h e   f o r m   o f   m o n o-
mer showing green fluorescence. When the ΔΨm is 
high, JC-1 forms polymers emitting red fluorescence. 
The  average  fluorescence  intensity  of  10  randomly 
selected  visual  fields  was  calculated  with  IPP  soft-
w a r e ,   a n d   t h e   r a t i o   o f   r e d   f l u o r e s c e n c e   i n t e n s i t y   t o  
green  fluorescence  intensity  indicates  the  level  of 
ΔΨm.  Reduction  in  this  ratio  implies  a  decline  in 
ΔΨm.  
Expressions of MDR1 and Bax by Western blot 
Cells  from  different  groups  were  lysed  with 
p r o t e i n   l y s i s   b u f f e r ,   a n d   t h e   c o n c e n t r a t i o n   o f   t o t a l  
protein in the supernatant was measured using BCA 
method. After denaturation by boiling, 20 µg of total 
p r o t e i n   w e r e   s e p a r a t e d   b y   1 0 %   p o l y a c r y l a m i d e   g e l  
electrophoresis  and  then  transferred  onto  PVDF 
membrane (Roche) by semi-d r y   t r a n s f e r .   B l o c k i n g   w a s  
done with 5% non-f a t   m i l k   a t   r o o m   t e m p e r a t u r e   f o r   1  
h. Then, these membranes wer e   i n c u b a t e d   w i t h   p r i-
mary antibodies (1:500 for MDR1 and 1:1000 for Bax) 
overnight  at  4  ℃.   A f t e r   w a s h i n g   w i t h   T B S T   ( 0 . 0 5 %  
Tween-20  in  TBS),  the  membranes  were  incubated 
with  horseradish  peroxidase  conjugated  secondary 
antibody  (l:  10,000)  at  37  ℃ for 1 h. The  membrane 
was then washed with TBST, and chemiluminescent 
s u b s t r a t e   E C I   w a s   u s e d   t o   v i s u a l i z e   t h e   b a n d s .   The 
optical  density  of  each  band  was  analyzed  with 
Gel-Pro gel analysis software (Bio-Rad Inc.). Relative 
protein  expressions  were  expressed  as  the  density 
ratio of target protein to respective β-actin. The aver-
a g e   e x p r e s s i o n   o f   e a c h   p r o t e i n   w a s   c a l c u l a t e d   f r o m   3  
independent experiments.  
MDR1 intracellular localization by laser scanning 
confocal microscopy 
F o r   M D R 1   i m m u n o f l u o r e s c e n c e   a s s a y ,   c e l l s   w e r e 
g r o w n   o n   s l i d e s   i n   a   6 -w e l l   p l a t e .   T w o   d a y s   l a t e r ,   M i-
t o T r a c k e r   R e d   i n   D M E M   ( 2 0 0   n m o l / L )   w a s   a d d e d  
f o l l o w e d   b y   i n c u b a t i o n   f o r   3 0   m i n   a t   3 7 ° C ,   a n d   t h e n  
cells  were  washed  twice  with  ice-cold  PBS  (0.01 
m o l / L ,   p H   7 . 2 ) .   T h e   c e l l s   w e r e   f i x e d   i n   i c e -cold  4% 
paraformaldehyde for 30 min followed by permeabi-
lization with 0.3 mg/mL Triton X-100  for  30  min  at 
room  temperature.  These  cells  were  washed  twice 
with 0.01 mol/L PBS and incubated in blocking buffer 
c o n t a i n i n g   g o a t   s e r u m   f o r   3 0   m i n   a t   r o o m   t e m p e r a-
ture.  Cells  w e r e   w a s h e d   t w i c e   w i t h   0 . 0 1   m o l / L   P B S  
and the expression of MDR1 was determined using 
the mouse monoclonal anti-P-gp antibody (1:100). The 
primary  antibodies  were  replaced  with  IgG  isotype 
control serving negative control. The incubations with 
primary antib o d y   w e r e   c a r r i e d   o u t   i n   b l o c k i n g   b u f f e r  
overnight at 4°C. After incubation with primary an-
t i b o d i e s ,   c e l l s   w e r e   w a s h e d   3   t i m e s   w i t h   0 . 0 1   m o l / L  
PBS,  and  incubated  with  FITC-conjugated  goat  an-
ti-mouse antibody (1:50) in dark for 1.5 h at 37°C. Cell 
nuclei  were  counterstained  with  DAPI 
(4,6-diamidino-2-phenylindole;  Sigma-Aldrich,  St. 
L o u i s ,   M O ,   U S A )   s o l u t i o n   ( 1   μ g / m L   i n   P B S )   f o r   5   m i n  
a t   r o o m   t e m p e r a t u r e .   A f t e r   w a s h i n g   w i t h   0 . 0 1   m o l / L  
P B S ,   c e l l s   w e r e   m o u n t e d   o n   s l i d e s   u s i n g   A n t i f a d e  
Mounting  Medium  (Beyotime  Institute  of  Biotech-
nology,  Jiangshu,  China).  Confocal  laser  scanning 
m i c r o s c o p i c   a n a l y s i s   w a s   p e r f o r m e d   w i t h   a   L e i c a   T C S  
SP2  confocal  laser  imaging  system  (Leica  Microsys-
tems, Wetzlar, Germany). To ascertain the localization Int. J. Biol. Sci. 2010, 6 
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o f   m i t o c h o n d r i a ,   c e l l s   w e r e   s t ained with MitoTracker 
R e d   C M X R o s   d y e .   A   m e r g e d   i m a g e   o f   g r e e n   M D R 1  
a n d   M i t o T r a c k e r   R e d   w a s   o b t a i n e d .   T o   a l l o w   q u a n-
titative analysis of the relative fluorescence intensity 
o f   c e l l s   b e t w e e n   g r o u p s ,   c e l l s   w e r e   s e l e c t e d   r a n d o m l y  
and  scanned  at  more  than  3  points.  Software  Im-
age-Pro Plus Version 6.0 (MediaCybernetics, Bethes-
d a ,   M D ,   U S A )   w a s   u s e d   t o   c a l c u l a t e   t h e   m e a n   f l u o-
rescence intensity. Average green fluorescence inten-
sity  per  cell  was  expressed  as  the  P-gp  protein  ex-
pression. 
Functional assay of mitochondrial P-gp 
M i t o c h o n d r i a l   f r a c t i o n   w a s   p r e p a r e d   a s   d e-
scribed below. Briefly, cells were washed twice with 
ice-c o l d   P B S ,   a n d   t h e   p e l l e t   w a s   s u s p e n d e d   i n   5 0 0  μl 
of ice-c o l d   b u f f e r   A   ( 2 0  mM  HEPES,  pH 7.5, 1.5 mM 
MgCl2, 10 mM KCl, 1 m M   E D T A ,   1  m M   E G T A ,   1  mM 
dithiothreitol, 0.1 mM phenylmethylsulfonyl fluoride, 
and 10 μg/ml each leupeptin, aprotinin, and pepsta-
tin A) containing 250 mM sucrose. To lyse the cells, 
c e l l   s u s p e n s i o n   w a s   p a s s e d   f i v e   t i m e s   t h r o u g h   a  
26-gauge needle fitted to a syringe. Unbroken cells, 
large  plasma  membrane  pieces  and  nuclei  were  re-
moved by centrifugation at 1000×g at 4°C for 10 min. 
The resulting supernatant was subjected to centrifu-
gation at 4°C for 20 min at 10,000 × g. The pellet frac-
t i o n   ( i . e .   m i t o c h o n d r i a )   w a s   f i r s t   w a s h e d   w i t h   t h e  
abo v e   b u f f e r   A   c o n t a i n i n g   s u c r o s e   a n d   t h e n   s o l u b i-
lized in 50 μ l   o f   T N C   b u f f e r   ( 1 0  mM  Tris–acetate, pH 
8.0, 0.5% Igepal CA-630, 5 mM CaCl2). The superna-
tant  was  re-centrifuged  at  100,000 × g  (4°C,  1 h)  to 
generate cytosol. 
Mitochondria were suspended in buffer   A   a n d  
kept on ice until the experiment was performed [9]. 
All  imaging  experiments  were  performed  at  room 
temperature  in  buffer  A.  The  whole  isolated  mito-
c h o n d r i a   f r o m   c u l t u r e d   c e l l s   w e r e   d i v i d e d   i n   t e s t  
tubes  to  evaluate  mitochondrial  autofluorescence  as 
w e l l   a s   t h e   u p t a k e   a n d   t h e   e f f l u x   o f   R h o   1 2 3   i n t o   a n d  
out of organelles. Rho 123 (5 μg/ml) was added to the 
samples  followed  by  incubation  for  4 min  at  room 
temperature in dark. After incubation, fluorescence of 
Rho  123  in  mitochondria  was  measured  with  a 
COULTER®  EPICS™  XL™  flow  cytometer  (Beckman 
C o u l t e r   I n c . ,   B r e a ,   C A ,   U S A ) .   T o   e s t i m a t e   t h e   R h o   1 2 3  
ef f l u x ,   m i t o c h o n d r i a   e x p o s e d   t o   R h o   1 2 3   w e r e  
re-suspended  in 2 m l   o f   b u f f e r   A   a n d   c e n t r i f u g e d   f o r  
5 min at 450×g at 4°C, afterwards they were washed 
once with  2 m l   o f   b u f f e r   A ,   b e f o r e   d i l u t i n g   t h e m   i n  
500 μl  of  buffer  A.  Samples  were  incubated  for 
another 6 m i n   a t   r o o m   t e m p e r a t u r e   t o   a l l o w   R h o   1 2 3  
efflux  from  mitochondria.  Then,  the  fluorescence  of 
R h o   1 2 3   w a s   d e t e r m i n e d   i n   e a c h   s a m p l e   w i t h   t h e  
COULTER® EPICS™ XL™ flow  cytometer and  meas-
u r e d   a t   a   f l o w   r a t e   o f   2 0 0 0   e v e n t s / s .   E x p e r i m e n t s  
were performed at least three times. 
Statistical analysis 
Data  were  expressed  as mean ± SD.  Statistical 
analysis  was  done  with  S P S S   v e r s i o n   1 3 . 0   s t a t i s t i c  
software package. Statistical significance between two 
groups was determined by paired or unpaired Stu-
dent's  t-test.  Comparisons  between  multiple  groups 
were performed by one-way analysis of variance. A 
value of P<0.05 was considered statistically signifi-
cant.  
Results  
Toxicity of CDDP to human HCC cells  
CDDP-resistant  SK-Hep1  (SK-Hep1/CDDP) 
cells were established by pulse exposure of SK-Hep-1 
c e l l s   t o   h i g h   c o n c e n t r a t i o n s   o f   C D D P .   A s   s h o w n   i n  
Table  1 ,   t h e   I C 50  o f   C D D P   i n   S K -Hep1  cells  and 
SK-H e p 1 / C D D P   c e l l s   w e r e   5 . 1 3   ±   0 . 0 9   μg/mL  and 
70.61  ±  1.06  μg/mL,  respectively.  SK-Hep1/CDDP 
cells were 13.76-fold more resistant to CDDP than the 
parent cells. The cross-resistance of SK-Hep1 cells and 
SK-H e p 1 / C D D P   c e l l s   t o   o t h e r   a n t i c a n c e r   d r u g s   ( D O X ,  
VCR  and  5-FU)  was  also  determined,  and  results 
showed  SK-Hep-1 / C D D P   c e l l s   a l s o   h a d  
cross-resistance to DOX, VCR and 5-FU.  
CCK-8   a s s a y   a l s o   s h o w e d   b o t h   I C 5 0   a n d   R I   o f  
SK-H e p 1   a n d   S K -Hep1/CDDP cells were decreased 
a f t e r   t r e a t m e n t   w i t h   m P T P   a g o n i s t   A T R ,   b u t   i n c r e a s e d  
after incubation with mPTP inhibitor CsA, which in-
creased the resistance to CDDP (Table 2).  
 
Table 1. IC50 a n d   R I   o f   S K -H e p 1   c e l l s   a n d   S K -Hep1/CDDP 
Cells (n=3) 
Drug 
(µg/mL) 
 
IC50 (mean ± SD)  Resistance 
index (RI) 
 
SK-Hep1  SK-Hep1/CDDP 
CDDP  5.13±0.09  70.61±1.06*  13.76 
DOX  0.74±0.04  4.13±0.23
*  5.58 
VCR  0.76±0.02  2.28±1.06*  3.12 
5-FU  12.49±0.27  52.79±3.85*  4.23 
 
* P<0.01 vs parental cells. SK-Hep1 cells and SK-Hep1/CDDP cells 
were exposed to designed concentrations of CDDP, DOX, VCR and 
5-FU for 24 h and CCK-8 assay was performed. The IC50 were cal-
culated. Data of 3 independent experiments are averaged and then 
expressed as means ± SD. RI = (IC50 SK-Hep1/CDDP cells)/(IC50 
SK-Hep1 cells). 
SD: standard deviation; IC50: half maximal inhibitory concentration. 
 
 
 Int. J. Biol. Sci. 2010, 6 
 
http://www.biolsci.org 
777 
Table 2. Toxicity of CDDP to HCC cells (n=3) 
groups  IC50 (μg /ml)  RI 
SK-Hep1  5.13±0.09   
SK-Hep1+CsA  6.25±0.03a  1.22 
SK-Hep1+ATR  2.53±0.08a  0.49 
SK-Hep1/CDDP  70.61±1.06  13.76 
SK-Hep1/CDDP+CsA  84.22±1.03b  16.42 
SK-Hep1/CDDP+ATR  30.27±0.67b  5.9 
a P<0. 05, vs SK-Hep1 cells. bP<0.05, vs SK-Hep1/CDDP cells. 
 
Detection of apoptotic rate by Annexin V/PI 
double staining 
After treatment with 10 µg / m L   C D D P   f o r   2 4   h ,  
the apoptotic rate of SK-Hep1 cells (6.95±0.29%) was 
significantly higher than that of SK-Hep1/CDDP cells 
(2.17±0.11%, P<0.01). If CDDP treated cells were in-
cubated with additional 1 µM   o f   C s A   f o r   2 4   h ,   t h e  
apoptotic rates of SK-Hep1 cells and SK-Hep1/CDDP 
cells  were  significantly  decreased  (5.11±0.18%  and 
0.86±0.14%, respectively) when compared with those 
with  CDDP  treatment  alone  (P<0.05).  These  results 
suggest that inhibition of mPTP opening can reduce 
t h e   s e n s i t i v i t y   o f   c a n c e r   c e l l s   t o   C D D P -induced 
apoptosis.  On  the  contrary,  treatment  with  mPTP 
agonist (20 µM ATR) increases the apoptotic rates of 
both  types of cells (24.61±1.03% and 6.18±1.13%, re-
spectively), which are also significantly higher than 
those  with  CDDP  treatment  alone.  These  findings 
indicate that promoting the mPTP opening can rela-
tively  enhance  the  cellular  sensitivity  to 
CDDP-induced  apoptosis and increase the apoptosis 
of drug-resistant cells after CDDP treatment (Fig. 1). 
Protein expression of MDR1 and Bax 
The relative expressions of MDR1 and Bax were 
shown  in  Fig. 2 .   T h e   M D R 1   e x p r e s s i o n   w a s   s i g n i f i-
cantly increased in SK-Hep1/CDDP cells when  com-
p a r e d   w i t h   S K -Hep1 cells (P<0.01), but there were no 
significant differences in the MDR1 expression after 
a d d i t i o n   o f   m P T P   a g o n i s t   o r   i n h i b i t o r .   T h e   B a x   e x-
pression was markedly decreased in SK-Hep1/CDDP 
c e l l s   w h e n   c o m p a r e d   w i t h   S K -Hep1  cells  (P<0.01). 
A f t e r   a d d i t i o n   o f   C s A ,   B a x   e x p r e s s i o n s   i n   b o t h  
SK-H e p 1   c e l l s   a n d   S K -Hep1/CDDP  cells  were  re-
duced to 1.47±0.03 and 0.39±0.03, respectively, which 
were significantly lower than those of untreated cells 
(P<0.01 and P<0.05, respectively); while the Bax ex-
pressions in SK-Hep1 cells and SK-Hep1/CDDP cells 
were  increased  to  4.12±0.03  and  0.91±0.03,  respec-
tively, which were significantly higher than those of 
untreated cells  (P<0.01),  after  ATR  treatment  (Table 
3).  
 
Table 3. Expressions of MDR1and Bax (n=3) 
groups  MDR1  Bax 
SK-Hep1  0.58±0.02  3.53±0.12 
SK-Hep1+CsA  0.56±0.01a  1.47±0.03c 
SK-Hep1+ATR  0.54±0.01a  4.12±0.03c 
SK-Hep1/CDDP  1.36±0.04c  0.59±0.02c 
SK-Hep1/CDDP+CsA  1.33±0.02b  0.39±0.03d 
SK-Hep1/CDDP+ATR  1.35±0.03b  0.91±0.03d 
Data were expressed as means ± SD (n = 3 per group). 
a: vs SK-Hep1 cells, P>0.05; b: vs SK-Hep1/CDDP cells, P>0.05; c: vs 
SK-Hep1, P<0.01; d: vs SK-Hep1/CDDP, P<0. 05.  
 
 
Detection of ΔΨm by flow cytometry 
T h e   Δ Ψ m   o f   b o t h   S K -Hep1  cells  and 
SK-Hep1/CDDP  cells  was  decrease  significantly 
(P<0.05) after 24 h of treatment with 10 µg/mL CDDP 
(Fig.  3 ) .   T h e   s i m u l t a n e o u s   a d d i t i o n   o f   1   µM  mPTP 
inhibitor CsA militates the reduction of ΔΨm; while 
t h e   a d d i t i o n   o f   m P T P   o p ener  ATR  exacerbates  the 
reduction  of  ΔΨm.  Both  differences  are  statistically 
significant (P<0.05).  
 
Evaluation of MDR1 distribution by laser scan-
ning confocal microscopy 
Intracellular  distribution  of  MDR1  was  deter-
mined by immunofluorescence. Confocal microscopic 
a n a l y s i s   c o n f i r m e d   t h a t   t h e   e x p r e s s i o n   o f   M D R 1   w a s  
elevated in SK-H e p 1 / C D D P   c e l l s   a n d   S K -Hep1  cells 
(Fig.  4A).  MDR1  was  localized  around  the  nuclear 
membranes.  To  further  assess  the  localization  of 
MDR1,  a  double  stain  with  MitoTracker  Red  and 
DAPI  was  performed.  The  green  fluorescence  was 
ubiquitous.  Fig.  4A  showed  the  relative  levels  of 
MDR1/P-gp (green fluorescence) in SK-Hep1/CDDP 
cells (above) and parental SK-H e p 1   c e l l s   ( b e l o w )   d e-
termined by confocal microscopy. 
The results of quantitative assessment are shown 
in  Fig.  4B.  CDDP-resistant  cells  had  pronounced 
higher levels of green fluorescence and higher mean 
o p t i c a l   d e n s i t y   w h e n   c o m p a r e d   w i t h   S K -Hep1 cells 
(P<   0 . 0 5 ) .   M e a n w h i l e ,   a f t e r   t r e a t m e n t   w i t h   A T R   o r  
CsA, MDR1/P-gp fluorescence was increas e d   o r   r e-
duced, respectively.  
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Figure 1. Apoptosis detected by Annexin V­FITC/PI staining. 
※P < 0.05 vs SK-Hep1 cells in 10 µg/mL CDDP.
※※P < 0.05 vs 
SK-Hep1/CDDP cells in 10 µg/mL CDDP. 
 
Fig 2. E f f e c t s   o f   A T R   a n d   C s A   o n   M D R 1   a n d   B a x   e x p r e s s i o n s   i n   S K -Hep1/CDDP cells and SK-H e p 1   c e l l s .   C e l l s   o f   d i f f e r e n t  
groups were maintained in humidified air with 5% CO2, and harvested to determine the expressions of MDR1 (A) and Bax 
(B) by western blot. (1. SK-Hep1; 2. SK-Hep1/CDDP; 3. SK-H e p 1   + C s A ;   4 .   S K -Hep1/CDDP+CsA; 5. SK-Hep1 +ATR; 6. 
SK-Hep1/CDDP+ATR.) Int. J. Biol. Sci. 2010, 6 
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Fig 3. Influence of ΔΨm by mPTP intervention. The ΔΨm w a s   e x p r e s s e d   a s   a   r a t i o   o f   J C -1 aggregated to monomer 
fluorescence after different treatments (n=10 images). *P<0.05 vs SK-Hep1 cells, **P< 0.05, vs SK-Hep1/CDDP cells. Int. J. Biol. Sci. 2010, 6 
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Fig 4. Confocal laser scanning microscopy for MDR1/P-gp intracellular distribution in resistant SK-Hep1/CDDP cells and 
parent SK-Hep1 cells. 
 
 
SK-Hep1/CDDP cells and SK-Hep1  cells  were 
simultaneously incubated with 200 nm of MitoTrack-
er  Red  f o r   1 5   m i n   a n d   s u b s e q u e n t l y   f i x e d   a n d   i m-
munostained  with  anti-P-glycoprotein  antibody. 
Then,  cells  were  stained  with  FITC-conjugated  sec-
ondary  antibody  (green)   a n d   D A P I   ( b l u e )   a n d   s u b-
jected to confocal microscopy. Representative images 
a r e   s h o w n .   S c a l e :   1 0   μ m .   T h e   c o -localization of Mito-Int. J. Biol. Sci. 2010, 6 
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Tracker and P-g p   w a s   d e m o n s t r a t e d   b y   t h e   y e l l o w  
fluorescence.  These  figures  are  representative  from 
three  separate  experiments.  CDDP-resistant  cells 
demonstrated pronounced higher levels of green flu-
orescence  and  higher  mean  optical  density  when 
c o m p a r e d   w i t h   S K -Hep1  cells  (P<0.05).  After  treat-
m e n t   w i t h   A T R   o r   C s A ,  MDR1/P-g p   f l u o r e s c e n c e   w a s  
significantly  increased  or  reduced,  respectively 
(P<0.05.a,vs  SK-Hep1;b,vs  SK-Hep1+ATR;c,vs 
SK-Hep1+CsA.). 
Evaluation of P-gp-mediated accumulation and 
efflux of Rho 123 in cells 
I s   t h e   P -g p   i n   m i t o c h o n d r i a   o f   t h e   c u l t u r e d   c e l l s  
functionally  active?  As  shown  in  Table  4,  Rho  123 
accumulated in  mitochondria  of  SK-Hep1 cells in a 
greater  amount  than  in  SK-Hep1/CDDP  cells  and, 
o n c e   R h o   1 2 3   w a s   r e m o v e d   f r o m   t h e   i n c u b a t i o n   m i x-
ture,  fluorescence  intensity  was  more  rapidly  de-
creased in the mitochondria of SK-Hep1/CDDP cells 
when  compared  with  the  mitochondria  of  SK-Hep1 
cells. 
 
Table 4. Accumulation and efflux of Rho 123 in SK-Hep1 
and SK-Hep1/CDDP cells by flow cytometry (n=5). 
Cells  Rho123 accumulation  Rho123 efflux 
SK-Hep1  42.0 ± 1.3  29.8± 3.5 
SK-Hep1/CDDP   24.1 ± 2.7*   17.4± 1.9* 
*P<0.05, vs parental cells. Data were analyzed by two-way analysis 
of variance, and a value of P<0.05 was considered significant. 
 
 
Discussion 
A  CDDP resistant  SK-Hep1  HCC  cell  line  was 
established  in  the  present  study.  The  resistant  cells 
showed an increase of 13.76 f o l d s   i n   t h e   r e s i s t a n c e   t o  
CDDP as c o m p a r e d   t o   p a r e n t   S K -Hep1 cells. The re-
sistant  cells  also  highly  expressed  MDR1  and  had 
decreased expression of apoptotic protein Bax.  
MDR1 expression has been considered to be as-
s o c i a t e d   w i t h   t h e   r e s i s t a n c e   t o   a d r i a m y cin  and  vin-
cristine,  but  not  to  cisplatin[10,11].  However,  the 
MDR1 was over-expressed in myelogenous leukemia 
cells[12]  and  HCC  cell  lines  [13]  after  CDDP  treat-
ment.  Recent  studies  showed  that  HCC  expressed 
MRP1,  MDR1,  MRP3  and  breast  cancer  resistance 
protein  (BCRP/ABCG2),  and  these  proteins  render 
c a n c e r   c e l l s   t o   b e   a   M D R   p h e n o t y p e   [ 1 4 , 1 5 ] .   I n   t h e  
present study, M D R 1   w a s   s i g n i f i c a n t l y   u p -regulated 
in  CDDP  -resistant  SK-Hep1  cells,  suggesting  that 
MDR1 is also involved in the resistance of cancer cells 
to CDDP.  
T h e   r e g u l a t o r y   e f f e c t s   o f   A T R   a n d   C s A  on the 
CDDP-induced  cytotoxicity  were  examined  in  the 
resistant cells. The apoptotic rate was also decreased 
in SK-Hep 1/CDDP cells, and their ability to counte-
ract  the  chemotherapy  induced  apoptosis  was  sub-
sequently  elevated.  After  incubation  with  mPTP 
a g o n i s t   ( A T R ) ,   t h e   I C 5 0 ,   R I ,   a n d   c e l l   s u r v i v a l   r a t e   o f  
both SK-Hep1 cells and SK-Hep1/CDDP cells against 
CDDP were decreased. T h i s   m a y   b e   a s   a   r e s u l t   o f   i n-
creased  apoptosis  and  reduced  cellular  ΔΨm.  The 
protein ex p r e s s i o n   o f   M D R 1   w a s   n o t   a f f e c t e d ,   b u t   t h e  
Bax expression was increased. After treatment with 
m P T P   i n h i b i t o r   ( C s A ) ,   t h e   I C 5 0 ,   R I ,   a n d   c e l l   s u r v i v a l  
rate  of  SK-Hep1  cells  and  SK-Hep1/CDDP  cells 
against CDDP were increased, and the apoptotic rate 
decreased  (compared  to  SK-H e p 1   c e l l s ) .   P r o t e i n   e x-
p r e s s i o n   o f   M D R 1   w a s   n o t   a f f e c t e d ,   b u t   t h e   B a x   e x-
pression was reduced.  
M D R   i s   a   c r i t i c a l   p r o b l e m   i n   t h e   c h e m o t h e r a p y  
of cancer. Use of MDR reversal agents in combination 
with anti-cancer drugs is an important strategy   i n   t h e  
c h e m o t h e r a p y   a i m i n g   t o   c o u n t e r a c t   t h e   M D R   o f   c a n-
c e r .   T h e   m e c h a n i s m   u n d e r l y i n g   t h e   M D R   o f   c a n c e r  
cells is complicated, and studies suggest that MDR is 
m a i n l y   r e l a t e d   t o   t w o   t y p e s   o f   c l a s s i c a l   m e m b r a n e  
transporter proteins in the cancer cells [16]. One be-
longs to the ATP-binding cassette (ABC) transporter 
superfamily including  P-gp/ABCB1, MRP1/ABCC1, 
and  BCRP/ABCG2,  which  have  the  ener-
gy-d e p e n d e n t   p u m p   f u n c t i o n   a n d   c a n   e x p o r t   a   v a r i e t y  
of  intracellular  substrates  including  the  anticancer 
drugs across the cancer cell membrane [17]. The other 
belongs  to  solute  carrier  transporter  superfamily, 
which  controls  the  intracellular  absorption  of  anti-
cancer drugs. Over-e x p r e s s i o n   o f   t h e s e   t w o   t y p e s   o f  
transporter  proteins  mediates  the  drug-resistance  of 
cancer  cells.  Kojima  et  al.  have  reported  that 
over-e x p r e s s i o n   o f   M D R 1   ( P -gp,  ABCB1)  in  cancer 
c e l l s   c a n   i n h i b i t   t h e   r e l e a s e   o f   m i t o c h o n d r i a l   c y t o c h-
rome c into cytoplasm and subsequently inhibit the 
caspase-dependent  apoptosis  [18,19].  Similarly,  the 
over-expressi o n   o f   B C R P / A B C G 2 ,   a   m e m b e r   o f  
ATP-binding cassette transporter protein family, can 
a l s o   e n h a n c e   t h e   a b i l i t y   o f   c e l l s   t o   c o m b a t   w i t h   a p o p-
tosis [20]. Recently, mitochondria have become one of 
important targets in screening novel anticancer drugs. 
Regulation  of  mitochondrial  function  can  not  only 
p r o t e c t   t h e   n o r m a l   c e l l s   f r o m   t h e   i n i t i a t i o n   o f   a p o p t o-
s i s ,   b u t   a l s o   i n d u c e   t h e   r e l e a s e   o f   a p o p t o t i c   p r o t e i n s ,  
l e a d i n g   t o   a p o p t o s i s   o f   c a n c e r   c e l l s   [ 2 1 ] .   A s   a   m u l t i-
protein complex locating between the inner and outer 
membranes of  mitochondria,  mPTP plays  a  critical 
role in the apoptosis mediated by the mitochondrial 
membrane permeability [22,23]. The escape from and Int. J. Biol. Sci. 2010, 6 
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antagonism of apoptosis are key factors, leading to 
resistance of cancer cells to chemotherapeutic drugs. 
Our results indicated the promotion of mPTP opening 
could  reduce  the  drug-resistance  and  increase  the 
apoptosis of cancer cells. However, the regulation of 
m P T P   d i d   n o t   a f f e c t   t h e   M D R 1   a c t i v i t y   b u t   c o u l d   r e-
gulate  the  protein  expression  of  Bax,  which  further 
affects  the  sensitivity  of  drug-resistant  cells  to  che-
motherapeutic agents. Therefore, our study suggests 
that  modulation  of  mPTP  function  can  affect  the 
apoptosis of SK-Hep1/CDDP cells. 
Since  P-gp  is  expressed  in  Golgi  and  nuclear 
membrane [24,25], it may be expressed in mitochon-
d r i a   w h e r e   i t   i n t e r f e r e s   w i t h   t h e   m o l e c u l a r   m e c h a n-
isms  of  apoptosis  [26].  Our  results  indicated  P-gp 
mitochondrial  localization  in  SK-Hep1/CDDP  cells 
was increased when compared with the parental cells, 
and the P-gp translocation into mitochondria was also 
c h a n g e d   w i t h   t h e   t r e a t m e n t   b y   A T R   o r   C s A .   M i t o-
chondrial  expression  of  P-g p   c a n   p r o t e c t   t h e   m i t o-
chondrial DNA from anticancer drugs induced dam-
age[9,27]. Moreover, it is involved in the mechanism 
b y   w h i c h   M D R   c e l l s   b l o c k   t h e   r e lease of cytochrome c 
from mitochondrial into cytoplasm[18]. 
Is  the  mitochondrial  P-g p   i n   M D R   c e l l s   f u n c-
tionally active? To investigate the mitochondrial P-gp 
f u n c t i o n ,   a c c u m u l a t i o n   a n d   e f f l u x   o f   R h o   1 2 3 ,   a   m i-
tochondrion  fluorescent  probe  with  strong  analogy 
with  anticancer  drugs,  were  evaluated  in  isolated 
m i t o c h o n d r i a   o f   p a r e n t a l   c e l l s   a n d   C D D P -resistant 
cell  lines.  Results  of  these  experiments  completely 
a g r e e   w i t h   t h o s e   o b t a i n e d   i n   w h o l e   c e l l s .   R h o   1 2 3   a c-
cumulation was significantly reduced in isolated mi-
tochondria of MDR cells as compared to those from 
t h e i r   p a r e n t a l   c e l l s .   R e d u c e d   f l u o r e s c e n c e   o f   m i t o-
c h o n d r i a   o f   M D R   c e l l s   w a s   p r o b a b l y   d u e   t o  
P-gp-mediated Rho 123 efflux. 
O n e   q u e s t i o n   i s   h o w   P -gp  interferes  with  the 
apoptosis.  It  was  shown  that  P-gp  over-expressing 
cells did not release cytochrome c from mitochondria 
o n c e   e x p o s e d   t o   a n   a p o p t o t i c   s i g n a l .   D o e s   P -gp play a 
r o l e   i n   t h i s   p r o c e s s ?   I t   h a s   b e e n   s h o w n   t h a t   c a s p a s e -3, 
a key actor in apoptosis, cleaves P-gp [28]. We specu-
l a t e   t h a t   t h e   c l e a v a g e   o f   P -gp  by  caspase-3  has  a 
feed-b a c k   r o l e   i n   t h e   s u p p r e s s i o n   o f   a p o p t o s i s .   H o w-
ever, we cannot exclude the possibility that the loop 
P-gp caspase-3-induced cleavage plays an enhancing 
role in the elimination of P-gp expressing cells.  
In  conclusion,  the  present  study  demonstrated 
t h a t   t h e   p r o m o t i o n   o f   m P T P   o p e n i n g   i n c r e a s e d   t h e  
expression of apoptotic protein Bax leading to apop-
tosis of drug-resistant cells. P-gp was translocated to 
mitochondria,  and  functionally  activated  and  func-
t i o n e d   l i k e   a   p u m p   t o   e x t r u d e   t h e   a n t i c a n c e r   d r u g s  
f r o m   m i t o c h o n d r i a .   O u r   s t u d y   p r o v i d e s   a   n e w   s t r a t-
egy for anti-cance r   t h e r a p y   a n d   f o r   r e v e r s a l   o f   M D R   i n  
cancer cells.  
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